Rosuvastatin attenuates heart failure and cardiac remodelling in the ageing spontaneously hypertensive rat
Article
Article Title | Rosuvastatin attenuates heart failure and cardiac remodelling in the ageing spontaneously hypertensive rat |
---|---|
ERA Journal ID | 14693 |
Article Category | Article |
Authors | Loch, David (Author), Chan, Vincent (Author), Hoey, Andrew (Author) and Brown, Lindsay (Author) |
Journal Title | Basic and Clinical Pharmacology and Toxicology |
Journal Citation | 105 (4), pp. 262-270 |
Number of Pages | 9 |
Year | 2009 |
Place of Publication | United Kingdom |
ISSN | 0901-9928 |
1742-7835 | |
1742-7843 | |
Digital Object Identifier (DOI) | https://doi.org/10.1111/j.1742-7843.2009.00440.x |
Web Address (URL) | http://onlinelibrary.wiley.com/doi/10.1111/j.1742-7843.2009.00440.x/pdf |
Abstract | 3-hydroxy-3-methylglutaryl(HMG)-Coenzyme(Co)A reductase inhibitors such as rosuvastatin may improve clinical status in patients with hypertension and heart failure. The ageing spontaneously hypertensive rat (SHR) closely mimics the chronic heart failure disease process observed in humans. This study examined the structural and functional changes in the cardiovascular system of 15-month-old SHR and normotensive Wistar-Kyoto (WKY) rats treated with rosuvastatin (20 mg/kg/day perorally) for 24 weeks. Cardiovascular structure and function were monitored serially by echocardiography. At 21 months, ex vivo Langendorff, electrophysiological or histological studies were performed. Chronic rosuvastatin treatment attenuated elevations of left ventricular wet weight (mg/g body weight: 21-month WKY, 2.30 ± 0.04; 15-month SHR, 3.03 ± 0.08; 21-month SHR, 4.09 ± 0.10; 21-month SHR + rosuvastatin, 3.50 ± 0.13), myocardial extracellular matrix content (% left ventricular area: 21-month WKY, 7.6 ± 0.5; 15-month SHR, 13.2 ± 0.8; 21-month SHR 19.6 ± 1.0; 21-month SHR with rosuvastatin 14.6 ± 1.2) and diastolic stiffness (κ: 21-month WKY, 24.9 ± 0.6; 15-month SHR, 26.4 ± 0.4; 21-month SHR, 33.1 ± 0.8; 21-month SHR + rosuvastatin, 27.5 ± 0.6) as well as attenuating the deterioration of systolic and diastolic function (fractional shortening %: 21-month WKY, 66 ± 2; 15-month SHR, 51 ± 3; 21-month SHR, 38 ± 3; 21-month SHR + rosuvastatin, 52 ± 4). There was no effect on the increased systolic blood pressure, plasma low-density lipoprotein concentrations or the prolonged action potential duration. Thus, chronic rosuvastatin treatment may attenuate myocardial dysfunction in heart failure by preventing fibrosis. |
Keywords | rosuvastatin; heart failure; cardiovascular function; diastole; echocardiography; extracellular matrix; heart electrophysiology; heart left ventricle; heart muscle |
ANZSRC Field of Research 2020 | 321401. Basic pharmacology |
Public Notes | Copyright 2009 The Authors |
Byline Affiliations | University of Queensland |
Centre for Biomedical Research |
https://research.usq.edu.au/item/9z2xy/rosuvastatin-attenuates-heart-failure-and-cardiac-remodelling-in-the-ageing-spontaneously-hypertensive-rat
1977
total views36
total downloads2
views this month0
downloads this month